Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

NIH and Santhera Announce Positive Results of Study with SNT-MC17

The US National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) presented results of their recently completed clinical trial with SNT-MC17/idebenone in Friedreich’s Ataxia (FRDA). Data were presented by Dr. Nicholas Di Prospero at the 3rd International Scientific Friedreich’s Ataxia Conference in Bethesda, MD, on November 10 to 12. This six month double-blind, placebo-controlled trial was carried out in collaboration with Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases.

Read More: NIH and Santhera Announce Posi tive Results of Study with SNT-MC17

SHARE

FacebookTwitterLinkedInYoutube
Science D.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator